Verifying…
Home / Drug A–Z / Neoxon Eye/Ear Drops

Neoxon Eye/Ear Drops

NAFDAC Reg. No. C4-1777 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Neoxon Eye/Ear Drops
NAFDAC number
C4-1777
Active ingredient
Betamethasone (Betamethasone Sodium Phosphate); Neomycin sulfate
Strength
0.1%; 0.5%
Form
Ear/eye drops
Pack size
1 x 10 mL
Manufacturer
Not listed
Applicant (holder)
Freshborn Industries Ltd
Approved
3 Aug 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
2 Aug 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Neoxon Eye/Ear Drops is on the NAFDAC register with an active registration (C4-1777). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Neoxon Eye/Ear Drops is used for

From the official U.S. FDA label for betamethasone (betamethasone sodium phosphate), the active ingredient registered with NAFDAC.

What it is used for

Betamethasone dipropionate cream (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Betamethasone dipropionate cream (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. ( 1 )

Possible side effects

The most common adverse reaction reported in 0.4% of adult patients is stinging. ( 6.1 ) The most common adverse reactions reported in 10% of pediatric patients are signs of skin atrophy, telangiectasia, bruising, shininess. ( 6.1 , 8.4 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. …

Do not use if

Betamethasone dipropionate cream (augmented), is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. Hypersensitivity to any component of this medicine. ( 4 )

Warnings

Effects on endocrine system: Betamethasone dipropionate cream (augmented) can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factor(s) include the use of high-potency topical corticosteroids, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop. ( 5.1 , 8.4 ) Ophthalmic Adverse Reactions: Betamethasone dipropionate cream (augmented) may increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist for evaluation. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary There are no available data on betamethasone dipropionate cream (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. …

Storage

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Neoxon Eye/Ear Drops

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Neoxon Eye/Ear Drops

What is in Neoxon Eye/Ear Drops?

Neoxon Eye/Ear Drops contains Betamethasone (Betamethasone Sodium Phosphate); Neomycin sulfate (0.1%; 0.5%), as ear/eye drops, according to its NAFDAC registration record.

Is Neoxon Eye/Ear Drops registered with NAFDAC?

Yes. Neoxon Eye/Ear Drops is listed on the NAFDAC register under registration number C4-1777, and its registration is active as of 27 October 2026.

Has Neoxon Eye/Ear Drops been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Neoxon Eye/Ear Drops in our automatically synced alert list.

How can I check that my pack of Neoxon Eye/Ear Drops is genuine?

Run a free authenticity scan with the NAFDAC number C4-1777, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Neoxon Eye/Ear Drops used for?

Betamethasone dipropionate cream (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Betamethasone dipropionate cream (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (Summarised from the official U.S. FDA label for betamethasone (betamethasone sodium phosphate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Neoxon Eye/Ear Drops? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.